Hematologic Malignancies
Specialty Channel

Featured Article
Premal Lulla, MBBS, discusses his team's study on the use of nonengineered T-cells for the treatment of patients with HL and NHL.
Patients with NHL with intermediate risk for FN maintain that risk even with pegfilgrastim prophylaxis, according to research presented at the NCCN Annual Conference.
Study findings have led experts to suggest that comorbidities in patients with non-Hodgkin’s lymphoma do not present randomly, but have distinct patterns, according to research presented at the NCCN…
The current protocol for monitoring the response to chemo in patients with ALL is a bone marrow biopsy, but a better one may exist, according to data presented at the NCCN Annual Conference.
Study findings lead experts to suggest that the prevalence of DLBCL and FL will likely rise in the United States and Europe, according to research presented at the NCCN Annual Conference.
True or false: The FDA has approved tazemetostat for the treatment of patients with confirmed EZH2-positive relapsed/refractory FL.
In a study of patients with light chain (AL) amyloidosis, daratumumab plus CyBorD was shown to produce robust responses and was well-tolerated.
At the virtual Great Debates & Updates in Hematologic Malignancies, Dr Mikhael presented emerging therapies in multiple myeloma (MM).
At the virtual Great Debates & Updates in Hematologic Malignancies, Jonathon Cohen, MD, presented standard treatment regiments and novel agents for the treatment of MCL.

News

The FDA has approved isatuximab-irfc plus carfilzomib and dexamethasone for the treatment of adults with relapsed/refractory MM given 1 to 3 previous lines of therapy.
Patients with NHL with intermediate risk for FN maintain that risk even with pegfilgrastim prophylaxis, according to research presented at the NCCN Annual Conference.
Study findings have led experts to suggest that comorbidities in patients with non-Hodgkin’s lymphoma do not present randomly, but have distinct patterns, according to research presented at the NCCN…
The current protocol for monitoring the response to chemo in patients with ALL is a bone marrow biopsy, but a better one may exist, according to data presented at the NCCN Annual Conference.

Interactive Features

True or false: The FDA has approved tazemetostat for the treatment of patients with confirmed EZH2-positive relapsed/refractory FL.
True or false: The FDA approved brentuximab vedotin injection to include peripheral T cell lymphomas in newly-diagnosed Hodgkin lymphoma.
True or False: Brentuximab vedotin combined with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas.
True or False: Bortezomib maintenance therapy after transplantation yields no positive effect in young patients with MCL.
Stay in the know.
OncNet Newsletter